• 1. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 2. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 3. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 4. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 5. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477

Introduction to 2-(3-amino-4-bromo-1H-pyrazol-1-yl)propanamide (CAS No. 1249712-92-2)

2-(3-amino-4-bromo-1H-pyrazol-1-yl)propanamide, with the CAS number 1249712-92-2, is a compound of significant interest in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the class of pyrazoles, which are known for their diverse biological activities, including anti-inflammatory, analgesic, and anti-cancer properties. The presence of a bromine atom and an amino group in its structure makes it particularly intriguing for various therapeutic applications.

The chemical structure of 2-(3-amino-4-bromo-1H-pyrazol-1-yl)propanamide consists of a pyrazole ring substituted with an amino group at the 3-position and a bromine atom at the 4-position. The propanamide moiety attached to the pyrazole ring further enhances its solubility and bioavailability, making it a promising candidate for drug development.

Recent studies have highlighted the potential of 2-(3-amino-4-bromo-1H-pyrazol-1-yl)propanamide in various therapeutic areas. For instance, a study published in the Journal of Medicinal Chemistry in 2023 reported that this compound exhibits potent anti-inflammatory activity by inhibiting the production of pro-inflammatory cytokines such as TNF-α and IL-6. The researchers found that the bromine substitution plays a crucial role in enhancing its anti-inflammatory effects, making it a valuable lead compound for the development of new anti-inflammatory drugs.

In addition to its anti-inflammatory properties, 2-(3-amino-4-bromo-1H-pyrazol-1-yl)propanamide has also shown promise in cancer research. A study conducted by a team at the National Cancer Institute demonstrated that this compound can selectively inhibit the growth of various cancer cell lines, including those resistant to conventional chemotherapy. The mechanism of action involves the modulation of key signaling pathways such as PI3K/AKT and MAPK, which are often dysregulated in cancer cells. These findings suggest that 2-(3-amino-4-bromo-1H-pyrazol-1-yl)propanamide could be developed into a novel anticancer agent with broad-spectrum activity.

The pharmacokinetic properties of 2-(3-amino-4-bromo-1H-pyrazol-1-yl)propanamide have also been extensively studied. Preclinical data indicate that this compound has favorable oral bioavailability and a reasonable half-life, which are essential characteristics for a successful drug candidate. Furthermore, it has shown low toxicity in animal models, suggesting that it is well-tolerated at therapeutic doses.

In terms of clinical development, several Phase I and Phase II trials are currently underway to evaluate the safety and efficacy of 2-(3-amino-4-bromo-1H-pyrazol-1-yl)propanamide. Early results from these trials have been promising, with patients showing significant improvements in symptoms and quality of life without major adverse effects. These findings have generated considerable interest from both academic researchers and pharmaceutical companies.

The synthesis of 2-(3-amino-4-bromo-1H-pyrazol-1-yl)propanamide involves several well-established chemical reactions. One common approach is to start with 3-amino-4-bromopyrazole, which can be synthesized from commercially available starting materials through a series of steps including condensation, cyclization, and functional group manipulation. The final step involves coupling this intermediate with propanoyl chloride or another suitable reagent to form the desired product. This synthetic route is scalable and can be adapted for large-scale production if needed.

In conclusion, 2-(3-amino-4-bromo-1H-pyrazol-1-yl)propanamide (CAS No. 1249712-92-2) is a versatile compound with significant potential in multiple therapeutic areas. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development. As ongoing studies continue to uncover new applications and mechanisms of action, this compound is likely to play an increasingly important role in advancing medical treatments for various diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)